The concept of the therapeutic window in the choice of H 1-receptor antagonist

Advanced Studies in Medicine

Volumn 4, Issue 7 A, 2004, Pages

  Howarth, Peter H ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; CETIRIZINE; DESLORATADINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MACROLIDE; MIZOLASTINE; PLACEBO; TERFENADINE;

ALLERGIC RHINITIS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; SEDATION; SIDE EFFECT;

EID: 4143084790     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64(6):612-621.
2. Bronsky EA, Falliers CJ, Kaiser HB, Ahlbrandt R, Mason JM. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc. 1998;19(3):135-141.
3. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32(1):133-139.
4. Hansen GR. Loratadine in the high performance aerospace environment. Aviat Space Environ Med. 1999;70(9):919-924.
5. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy. 1999;29(suppl 3):133-142.
6. Howarth PH. H1-receptor antagonists in the rhinoconjunctivitis. In: Simons FER, ed. Histamine and H1-Receptor Antagonists in the Treatment of Allergic Disease. New York: Marcel Deker Inc; 2002:215-250.
7. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant manlelukast and lorotadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5):917-922.
8. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, asternizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol. 1990;86(4, pt 1):540-547.
9. Rivest J, Despontin K, Ghys L, Rihoux JP, Lachapelle JM. Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica. 1991;183(3):208-211.
10. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flore response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88(2):190-197.
11. Frossard N, Purohit A, Kovacs S, Vitow C, Georges G, Pauli G. Fexofenadine is superior to loratadine and desloratadine in onset of action of histamine-induced wheal and flare inhibition. Ann Allergy Asthma Immunol. 2003;90:124.
12. Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCI 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol. 2003;90(6):629-634.
13. Purohit A, Deslandes B, Pauli G, Frossard N. Fexofenadine and cetirizine have similar rapid onset of action and magnitude of effect as assessed by inhibition of histamine-induced wheal and flare. Ann Allergy Asthma Immunol. 2003;90:123.
14. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 mg and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(5):927-933.
15. Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine HCI 180 mg exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(4):354-361.
16. van Cauwenberge P, Juniper E. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30(6):891-899.
17. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489-498.
18. Hibbert J, Howarth PH. Antihistamines and cardiac arrhythmias. Prescribers J. 1994;34:31-35.
19. Hansten PD, Levy RH. Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution: focus on H1-receptor antagonists. Clin Drug Invest. 2001;21:587-596.
20. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27(8):866-871.
21. Hwang KK, Correll M, Offord SJ. Evaluation of desloratadine for absorption drug-drug interactions with ketoconazole. J Allergy Clin Immunol. 2001;107:153.
22. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 2001;23(3):451-466.
23. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11-20.
24. Banfield C, Gupta S, Marino M, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet. 2002;41(4):311-318.
25. White MV, Kaliner MA, Rothrock S, et al. Effect of grape-fruit juice on fexofenadine vs placebo in a skin wheal-and-flare challenge model. Presented at: the 22nd European Academy of Allergology and Immunology Congress; June 7-10, 2003; Paris, France.
26. White MV, Kaliner MA, Rothrock S, et al. Effect of orange juice on fexofenadine vs placebo in a skin wheal-and-flare challenge model. Presented at: the 22nd European Academy of Allergology and Immunology Congress; June 7-10, 2003; Paris, France.
27. Clarinex [package insert]. Kenilworth, NJ: Schering Corporation; 2000. Available at: http://www.spfiles. com/piclarinex.pdf. Accessed November 10, 2003.